Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06342921
Other study ID # ADC189-2022-01
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date December 7, 2022
Est. completion date June 30, 2024

Study information

Verified date March 2024
Source Jiaxing AnDiCon Biotech Co.,Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection. The main aim to answer: - Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study. - Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza. Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days. Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo.


Recruitment information / eligibility

Status Recruiting
Enrollment 675
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years to 65 Years
Eligibility Inclusion Criteria: 1. Patients aged 18 to 65 years (including the cut-off point, Phase II) or 12 to 65 years (including the cut-off point, Phase III) with a body weight = 20 kg, both sex; 2. Patients were diagnosed with Influenza A Virus Infection/Influenza B Virus Infection according to the following criteria: nasopharyngeal swab or oropharyngeal swab was positive under influenza rapid antigen test (RAT) (rapid influenza virus nucleic acid test or other rapid molecular diagnostic methods are also acceptable); and fever (ear temperature = 37.3°C or axillary temperature = 37.2°C), if taking antipyretics, ear temperature = 37.3°C or axillary temperature = 37.2°C after 4 hours taking antipyretics; at least one of the following symptoms are moderate or above (influenza symptom severity score = 2) related to influenza: systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue; respiratory symptoms: cough, sore throat, nasal congestion; 3. The time interval from the onset time of influenza to screening start = 48 hours. Definition of influenza onset: the fever (ear temperature =37.3°C or axillary temperature =37.2°C or oral temperature =37.7°C) (ear temperature, axillary temperature and oral temperature measurements are acceptable), or the onset of any systemic symptoms or respiratory symptoms related to influenza; 4. Fertile subjects (including their partners) agree to take effective contraceptive methods throughout the study period and 3 months after study. 5. Voluntary participation in this clinical study and signing of the informed consent. Exclusion Criteria: 1. Patients with known allergies to the test preparation, any of its components or related preparations (or severe allergic constitution), and who are judged by the investigator to have a safety risk for enter the trial; 2. Patients diagnosed as severe/critical flu at screening, as defined below: 1. Severe cases are defined as those meeting one of the following conditions: High fever over 3 days, accompanied by severe cough, expectoration, bloody sputum, or chest pain; rapid breathing, dyspnea, and cyanosis of the lips; mental changes such as slow response, drowsiness, restlessness, or convulsions; severe vomiting, diarrhea, and dehydration; complicated with pneumonia; significant exacerbation of the original underlying disease; 2. Critical cases are defined as those meeting one of the following conditions: Respiratory failure; acute necrotizing encephalopathy; shock; multiple organ dysfunction; 3. High-risk population in severe cases are defined as those meeting any of the following conditions, and who are judged by the investigator to have a safety risk in the trial: Patients with severe or poorly controlled underlying diseases, such as chronic respiratory diseases, liver diseases, chronic kidney diseases, severe hematological diseases, chronic congestive heart failure [New York Heart Association (NYHA) cardiac function classification III-IV], nervous system and neuromuscular diseases, metabolic diseases, etc.; Subjects with clinically significant abnormalities in the corrected QT interval (QTc> 450ms for males or QTc> 470ms for females) on electrocardiogram (QTcF calculated according to the Fridericia formula); Subjects with immunodeficiency, such as malignant tumor, organ or bone marrow transplantation, HIV infection, or taking immunosuppressants in the past 3 months; Subjects with other diseases requiring treatment with aspirin or salicylate drugs; Subjects with obesity [body mass index (BMI) greater than 30 kg/m2]. 4. Subjects with a known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, post-subtotal gastrectomy, etc.); 5. Subjects who had used anti-influenza virus drugs (oseltamivir, zanamivir, peramivir, favipiravir, arbidol, baloxavir, amantadine or rimantadine, etc.) within 2 weeks before screening or had received influenza vaccine within 6 months before screening; 6. Subjects with acute respiratory tract infection, otitis media, sinusitis or other infectious diseases such as bronchitis, pneumonia, tuberculosis or other infectious diseases within 2 weeks before screening; 7. Subjects with other bacterial or viral infections at the time of screening and need systemic antibacterial or antiviral treatment, or subjects with blood routine test: white blood cell count (WBC) > 10.0×109/L at the time of screening; 8. Pregnant or lactating women or positive pregnancy test. Pregnancy test is not required for women who have stopped menstruation for more than 2 years, confirmed postmenopausal women or women who have undergone hysterectomy, bilateral oophorectomy or tubal ligation surgery; 9. Suspected or confirmed history of alcohol or drug abuse; 10. Those who have participated in other drug clinical trials within 3 months before taking the drug; 11. Those who are not suitable for participation in the study in the judgment of the investigator.

Study Design


Intervention

Drug:
15 mg ADC189
Use only once during the whole study.
45 mg ADC189
Use only once during the whole study.
Placebo
Use only once during the whole study.

Locations

Country Name City State
China Rui Jin Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Jiaxing AnDiCon Biotech Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the severity of influenza All subjects recorded 7 symptoms associated with influenza (cough, sore throat, headache, nasal congestion, fever or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 points, none; 1 point, mild; 2 points, moderate; 3 points, severe) in a self-assessment on Dairy Card. 22 days
Primary the safety of study drug Collect all the Adverse Events during the whole study. 22 days
See also
  Status Clinical Trial Phase
Completed NCT04485481 - Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers Phase 1
Completed NCT03473236 - Phase 1A Safety Trial of Inhaled PK10571 (GB002) Phase 1
Not yet recruiting NCT03683953 - The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells Phase 1
Recruiting NCT05546567 - NOPARK Open Label Extension Study N/A
Recruiting NCT05413226 - Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility N/A
Recruiting NCT05112159 - Study of IPG1094 in Healthy Participants Phase 1
Completed NCT04689035 - A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144 Phase 1
Completed NCT04335045 - Phase I Study of PH100 (Ecklonia Cava Phlorotannins) Phase 1
Completed NCT05037227 - Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
Recruiting NCT05517291 - DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease N/A
Enrolling by invitation NCT06446778 - Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
Recruiting NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement Phase 4
Completed NCT05585463 - Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
Completed NCT04188821 - Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander N/A
Completed NCT03667430 - Safety Evaluation of Porous Silica in Men N/A
Completed NCT04499482 - Safety and Tolerability of Soy Fiber N/A
Completed NCT03141905 - Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease N/A
Completed NCT05244161 - A Quasi-experimental Evaluation of the Malezi Program in Tanzania N/A
Recruiting NCT03791372 - Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy Phase 1
Not yet recruiting NCT04774900 - Standardization of Ambulance Equipment